Clinical Trial Update: Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed [Phase 2]

View source ↗

Summary

A Phase 2 trial update reports results from testing cabozantinib, crizotinib, savolitinib, and sunitinib in patients with locally advanced or metastatic papilla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papillary Renal Cell Carcinoma
• Renal Cell Carcinoma
• Type Papillary Renal Cell Carcinoma

Drugs mentioned

• Cabometyx (cabozantinib)
• Savolitinib (savolitinib)
• Sutent (sunitinib)
• Xalkori (crizotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-09-02